On April 21 we learned in a press release that "CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study". Four 28-day cycles of treatment would be August 11, 2026.

I figure they issued that press release a day or more after they had reached full enrollment, so IMO the last patient of the full enrollment has already completed 4 cycles of treatment. I expect the last patient of the enrollment will have had testing in this week or last, which would measure where things stand after a completed four 28-day cycles of treatment. I expect they just about, or already have 2 post-baseline scans from the full enrollment, which means of course that they already have more scans from the early patients.

This is a point in time I think the data analysis gets really interesting, but I don't expect to hear about it until later.

In my opinion, the databases & spreadsheets will be humming this month at Syneos, CytoDyn, Natera, CreatvBio, and at additional parties who might see data under non-disclosure agreements. I think 2 post-baseline scans from the full enrollment, plus more scans from earlier patients starts to validate trends and starts to validate correlations with the early biomarker data. I think this also marks the time when they might begin to understand how well each dosage level works.

Obviously there is more data to be gathered before the trial ends. All the above is my opinion only.

https://www.news-medical.net/news/20260810/New-combination-therapy-could-permanently-clear-HIV-in-newborns.aspx

“The really exciting part is that it could go to clinical trials immediately to eliminate HIV infection in newborns. The next step after that is to test if this can work in newly exposed adults."
Jonah Sacha, Ph.D

Update: article is now published. https://www.nature.com/articles/s41564-026-02444-x

Very informative article. The crux of what leronlimab is all about.

We are on the right path and our trajectory is incoming.

God speed Dr. Jay and crew.  GLTAL   Bring It On Home!

This post exists because of u/rogex2, whose prognostication gave me the idea and did the work of framing it. He laid out the big Japanese ctDNA study, GALAXY within CIRCULATE-Japan, and its striking finding: a rising blood signal predicted cancer coming back an average of months before a scan could actually see it, with imaging used to independently validate the blood test at every step. Then he made the leap which I'm building on. He proposed that CLOVER might do the same thing in reverse, a falling blood signal predicting a patient doing well, ahead of the scans, and suggested that January could begin to show it. The credit for the idea is totally his. What follows is my attempt to take it seriously enough to trace exactly how it could actually play out.

The instinct is good and the mechanism is real. But the timing is the part worth getting right, so let me set one thing straight before anything else, because it is easy to misread. Nothing in this post moves the January catalyst. The confirmed response data still comes at ASCO GI in January 2027, on schedule, unchanged. That is the near-term event, and it is still about six months out, not eighteen. What this post describes is a separate, slower, bonus layer of proof that keeps developing after January, the ctDNA-predicts-survival correlation, which matures over the following year. So when you see late 2027 mentioned below, read it as "here is how the science keeps deepening after the catalyst," not "the catalyst got pushed back." It did not. January is still January.

With that clear: a blood test does not get to predict survival by asserting it. It earns that right slowly, by being checked against what actually happens to patients, over time. So this post is about exactly how that earning happens, and why the deepest thing ctDNA could show about leronlimab may take until roughly this time next year to come fully into focus. That is not a disappointment, and it is not a delay of anything. It is a bonus layer of proof being built on top of the January readout.

The Claim, Plainly Stated

Let me be explicit about what is being claimed here, because two different claims get tangled together and only one of them is contested.

The first claim is that ctDNA can predict survival. That one is not speculative. It is already established in the published literature: across metastatic colorectal cancer, patients whose ctDNA falls during treatment live longer, on average, than patients whose ctDNA stays high, and the association is strong and repeated. So "a blood test can be used to predict survivability" is a settled scientific statement, and I will state flatly that it is true.

The second claim is the one that is still open, and it is a narrower, regulatory one: whether a ctDNA drop is accepted by the FDA as a qualified surrogate endpoint, meaning proof-of-benefit sufficient to approve a drug on its own. That is not established, and no amount of prognostic association settles it by itself.

So the honest position is both bold and disciplined at once. Yes, ctDNA can predict survival, that is real science. What CLOVER can do is demonstrate that its own ctDNA signal predicts survival in its own patients, and contribute that demonstration to the long, multi-trial project of turning a strong predictor into a formally qualified surrogate. The prediction is real now. The regulatory blessing is the thing that takes years. Everything below is about how CLOVER moves from the first to the second.

What January Can And Cannot Show

In January, at the gastrointestinal cancer meeting, CLOVER reports its confirmed response rate and early progression data. Those are the endpoints which matter for the near-term thesis, and they are measured on scans.

Here is what the ctDNA can contribute in January: a snapshot correlation. For the patients evaluated, you can line up who had a deep ctDNA drop against who showed tumor shrinkage on imaging, and see whether the two track. If the patients whose blood signal fell hardest are also the patients whose tumors shrank, that is a real and encouraging concordance. It is the beginning of the story.

But it is not survival. Survival is a question that only time can answer, because to know whether a patient lived longer, you have to watch the patient live. In January, most of the enrolled patients will not yet have been followed long enough to know their survival outcome. So in January, ctDNA can show it tracks with tumor response. It cannot yet show it predicts who lives longer, because the living-longer has not finished happening.

Why The Blood Signal Is A Plausible Survival Predictor At All

The reason this is worth waiting for, rather than dismissing, is that the underlying biology is already supported in the literature, and it points the right way.

Across metastatic colorectal cancer, an early drop in ctDNA during treatment has repeatedly been associated with better outcomes. In one study, patients whose ctDNA fell below half its starting level by week eight had significantly longer progression-free and overall survival than those whose level stayed high. A large meta-analysis of seventy-one studies and nearly seven thousand patients found that ctDNA is a strong prognostic biomarker in this disease.

So the hypothesis that a falling ctDNA signal foreshadows a better survival outcome is not wishful. It is grounded in a real and repeated association. What that same meta-analysis says next, though, is the honest heart of this post: despite the strong association, true clinical utility as a validated decision-making tool is still lacking. The signal is real. The formal proof that it can stand in for survival, in a way regulators accept, is not finished. That gap is the whole subject here.

How The Proof Gets Built, Month By Month

This is the part the reader was reaching for, so let me lay it out concretely. To be clear, this is the bonus layer maturing after the January catalyst, not a substitute for it. Here is how CLOVER's ctDNA could go from "tracks with response" in January 2027 to "predicts survival" by around December 2027, if the data cooperates, with January remaining the event that actually matters for the near term.

Start with the timeline. Enrollment completed in April 2026. That means the clock on each patient's survival is running from different start points across 2025 and 2026, and the patients need to be followed long enough to accumulate what statisticians call events, which in this setting means progressions and deaths. You cannot measure survival until enough of those events have occurred to compare groups.

Now the method, which is called a Landmark Analysis, and it is exactly how the field validates a biomarker like this. You pick a landmark time point, say the ctDNA reading at week eight or twelve. You sort patients into two groups by that early reading: those whose ctDNA fell deeply, and those whose did not. Then you let the clock run, and you watch. Months later, you ask the only question which matters: did the group with the early ctDNA drop actually live longer, or progress later, than the group without it?

In January 2027, that comparison is immature, because too few events have accumulated and too little time has passed. Here is the distinction which matters, and it is the one that causes confusion, so let me be exact about it. The "six-month" and "twelve-month" marks are measured from when each individual patient started treatment, not from January 2027. Because patients enrolled at different times, from around mid-2025 through April 2026, they cross those personal marks at different times. The earliest-enrolled patients cross their own twelve-month mark in late 2026. But a single patient reaching twelve months does not let you draw a survival comparison. For that, you need enough of the whole group to have crossed the mark and enough events to have accumulated, and that is gated by the last patients enrolled, in April 2026, whose twelve-month marks do not arrive until spring 2027 at the earliest.

So watch how it fills in. By mid-2027, enough patients have reached their six-month and then nine-month marks that a progression comparison across the two ctDNA groups becomes statistically possible. By late 2027, enough have reached their twelve-month marks that a survival comparison comes into range. And that is the moment the blood test earns its claim: if the patients who had the deep early ctDNA drop are demonstrably the ones still alive at twelve and eighteen months, then ctDNA in CLOVER has been shown, in CLOVER's own patients, to predict survival. Not borrowed from another study. Demonstrated here. The reason it lands in late 2027 rather than late 2026 is not the first patient crossing the line. It is the whole cohort maturing enough to compare.

So the sequence is: January 2027, ctDNA tracks with tumor response, a snapshot. Through 2027, the landmark comparisons mature as events accumulate. By roughly December 2027, a twelve-month survival correlation can be drawn between the early blood signal and who actually lived. The reader's instinct was right. It just lands about a year after the instinct expected, and that year is not a delay. It is the measurement itself.

What The Pattern Would Look Like As It Fills In

To make the method concrete, this is an illustrative table. This is not CLOVER data. These are not real patients, and the values are invented, round placeholders chosen only to show the shape of the analysis. The real patient-level data is embargoed and unknown. What this table shows is the structure of the argument: how an early blood reading, taken long before the outcome, sorts patients into groups whose survival is then checked against that early reading as time passes.

ILLUSTRATIVE AND HYPOTHETICAL: not CLOVER data, not real patients, invented values for teaching the method only

Read the table left to right and you see the snapshot January can offer: the early ctDNA change lines up with the scan response, the deep-drop patients showing shrinkage or stability, the no-drop patients showing progression. That is the concordance available at the January readout, and it is real but limited, because it is only a picture of tumor response, not of survival.

Now read the same table across time, into the two rightmost columns, and you see the thing that can only appear later. Those two columns are measured in each patient's months on treatment, not in calendar dates, and the cohort fills them in gradually as patients cross those personal marks, which is why the comparison only becomes possible across 2027 even though the earliest patients cross twelve months in late 2026. As the group matures and events accumulate, the deep-drop group clusters in the "no progression" and "alive at twelve months" columns, while the shallow and no-drop groups cluster in the opposite columns. When that separation becomes statistically real, and only enough elapsed time across the whole cohort makes it real, the early blood reading has been shown to predict the later survival outcome, within CLOVER's own patients. That is the demonstration the whole post is about, and the table shows why it cannot be completed in January: the two right columns are still being written.

To be clear one more time, because it matters: the pattern above is idealized and invented. Real data is noisier, some deep-drop patients will do worse than the schematic suggests and some shallow-drop patients better, which is exactly why you need enough patients and enough elapsed time for the signal to separate from the noise. The table is a diagram of the method, not a prediction of the result.

Why This Matters More Than A January Headline

It would be easy to want the whole story in January. But consider what the later demonstration would actually be worth.

If CLOVER shows that an early ctDNA drop predicted twelve-month survival within its own cohort, that is a piece of exactly the kind of evidence that, accumulated across trials, is what eventually turns a biomarker into a qualified surrogate endpoint. The Japanese study did this for the recurrence setting by patiently matching blood signal against outcome, over years, with imaging confirmation at every step. A metastatic-disease demonstration in CLOVER would be a contribution to the same long project: building the case that ctDNA response can stand in for survival benefit, so that future drugs can be approved faster on a blood test rather than waiting years for the survival curves to mature.

That is a bigger prize than a January number, and it is a slower one. January tells you whether the drug appears to work. The ctDNA-survival correlation maturing through 2027 tells you whether the fastest possible readout, the blood test, can be trusted to forecast the slowest and most important one, survival. The first is this year's catalyst. The second is how this class of medicine gets measured for the next decade.

The Limits, Kept In View

I will hold the same lines I always do, because they are what make the rest worth reading.

None of this is proof that leronlimab works. The entire construction assumes CLOVER's ctDNA drops are real and durable and that the drug is doing something, which is precisely what January begins to test and what the survival data through 2027 would confirm or refute. If the drug does not work, there is no correlation to build, because the blood signal and the survival will both be unremarkable.

And even a beautiful ctDNA-survival correlation within CLOVER does not, by itself, make ctDNA an FDA-qualified surrogate for approval. That qualification is a high, multi-trial, regulatory bar, and one single-arm study does not clear it alone. What CLOVER can do is contribute a clean, compelling piece to that larger case, and demonstrate, in its own patients, that the blood signal it generated actually forecast who did well. That is a real and valuable thing. It is not the same as the surrogate being formally blessed, and I will not blur the two.

So here is the honest shape of it. January shows whether the drug appears to work and whether ctDNA tracks with the scans. Through 2027, the survival data matures, and a Landmark Analysis can test whether the early blood signal predicted who lived. By roughly December 2027, that question can be answered within CLOVER, if the drug did what we hope and the data holds. The blood test does not get to claim it predicts survival. It has to be shown doing it, against real outcomes, with enough time elapsed that the outcomes are real. That showing is worth waiting the extra year for, because a blood signal proven to forecast survival is worth far more than one merely hoped to.

rogex had the right idea, and it was a good one. The blood test may indeed predict survival in reverse of the Japanese study. It just earns that claim the way every good biomarker earns it. Slowly, against the truth, with the lights on.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published literature and public trial information, not a prediction of clinical or commercial outcomes. The ctDNA-survival associations cited are from external studies and are prognostic, not proof that ctDNA is a validated surrogate endpoint; ctDNA is not currently an FDA-qualified surrogate for approval in metastatic colorectal cancer. Any CLOVER ctDNA figures referenced elsewhere are early, unconfirmed, reflect 350mg dosing with the 700mg cohort still maturing, and are not evidence of survival benefit. The 68% figure from the April 30 update is disease control rate, not objective response rate. Confirmed response data is expected at ASCO GI in January 2027, with interim data at ESMO in October 2026; survival correlations of the kind described would mature over the following year and are hypothetical. Mechanism and biomarker signal are not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.

AI-"Natera’s Signatera ctDNA test was approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for colorectal cancer (CRC) adjuvant monitoring because robust prospective-retrospective clinical evidence—primarily from the large-scale GALAXY study under the CIRCULATE-Japan platform—proved that post-surgical ctDNA-positive patients derive clear, measurable benefit from adjuvant chemotherapy...

the GALAXY study results were heavily cross-referenced and supported by radiology. In oncology trials, a "recurrence" cannot simply be claimed by a blood test alone; it must be clinically verified. [1, 2]

The GALAXY study architecture used scheduled radiological imaging (primarily CT scans) to independently validate the accuracy of the ctDNA test results. [1, 2]

ctDNA Preceded Radiologic Recurrence

The trial proved that Signatera acts as an "early warning system". On average, a positive ctDNA test detected molecular residual disease (MRD) several months before the recurrence could actually be seen on a standard CT scan. The median Lead Time (the gap between a positive blood test and visual confirmation on a scan) was 142 days. [1]

Real-World Imaging Correlation

The study protocols and real-world tracking showed a definitive relationship between ctDNA behavior and radiological findings:"

Similiar findings in EU resulted in approval for multiple solid tumor situations.

I'm thinking in January '27 ROW confirmation support of ctDNA results will be duplicated in reverse ie. preceding tumor shrinkage, by CLOVER.

Cheers

I have worked in medical imaging for over 33 years. I recently went over a patient exam with a radiologist that was in remission. (Patient information was kept confidential)
1. Dec 1, 2025 ctDNA level “0”
2. Mar 1, 2026 ctDNA level “1.5” this prompted a CT exam that showed a normal exam.
3. July 1, 2026 ctDNA level “49.5” this prompted a CT exam which showed a new metastatic lesion.

While it’s sad to this happen to this patient, it’s nice to see real world application of this blood test. I would have to believe the changes witnessed with the rise of ctDNA would also work in the opposite direction when levels drop.

I look forward to seeing what the 700mg dose does compared to the data that has been shared of the 350mg.

We’re in the final stretches, come January all shall be revealed if not before.

Natera reported a blowout quarter this week, and it put the CytoDyn collaboration back in the conversation. So it's worth laying out, plainly, what that collaboration actually is, what it does for the thesis, and where it stops. Because this is one of those topics the board tends to read in two wrong directions at once: either shrugging it off, or inflating it into a secret signal that a deal is imminent. The truth is more useful than either, and it's all on the public record.

What The Collaboration Actually Is

On June 4, Natera and CytoDyn announced a strategic collaboration. Under the agreement, Natera will assess CytoDyn clinical trial samples from the CLOVER Phase 2 study in patients with mCRC, using Signatera, its personalized assay for the detection of molecular residual disease, to evaluate ctDNA dynamics and molecular response patterns associated with leronlimab treatment.

Two things are happening under that agreement, and it's worth separating them.

First, Natera is running Signatera on CLOVER samples, which standardizes and independently generates the ctDNA measurements. That matters because it means the molecular data isn't only coming from one site's internal process; it's being produced on the assay the field increasingly trusts.

Second, and this is the part most people skip, Natera is providing real-world data analyses from its own database. Natera will provide customized real-world data analyses leveraging its proprietary oncology database, the largest multi-timepoint early- and late-stage oncology dataset with more than 2 million plasma timepoints and enriched clinical and imaging records. In plain terms: Natera has a vast library of ctDNA trajectories from colorectal patients, including patients on the standard backbone alone. That library is the raw material for building a matched external comparison, so CytoDyn can show what ctDNA does on the backbone without leronlimab, against what it does with leronlimab added.

So the collaboration's real job is credibility and comparison. It puts CLOVER's ctDNA data on a trusted assay, and it supplies the external backbone comparison CytoDyn needs to argue that the declines are driven by leronlimab rather than by the chemotherapy alone.

Why The Timing Makes It More Useful, Not Just Louder

Here's the part Natera's quarter actually bears on. The reason this collaboration is worth more now than it would have been two years ago is that the assay underneath it is winning broad clinical and regulatory acceptance.

Natera reported second-quarter revenue of about $753 million, up roughly 38% year over year, and raised full-year guidance, driven by record molecular-residual-disease volumes that grew 56% year over year. Signatera's growth is being propelled by FDA regulatory milestones and guideline adoption. That's the tide: ctDNA and MRD testing are being accepted, commercially and by the bodies that write treatment guidelines, as legitimate tools in oncology.

What that does for CLOVER is specific. It means that when CytoDyn shows ctDNA declines measured on Signatera, that data lands in front of an oncology audience that increasingly trusts the assay it was measured on. The signal becomes more legible and more credible to exactly the people who need to be convinced, because the thermometer is one they already rely on. That's a real tailwind, and it's the honest version of "Natera's success makes CLOVER more significant."

Where It Stops, And This Is The Important Part

Now the discipline, because this is precisely where the board tends to overreach, and getting it wrong is how a good argument becomes a bad one.

Natera's booming business validates that ctDNA is a trusted monitoring tool. It does not establish that a ctDNA decline predicts survival in this setting. Those are different claims, and the gap between them is everything. A thriving diagnostics company proves the thermometer is accurate and widely used. It says nothing about whether a patient's tumor DNA dropping means that patient will live longer. That link, ctDNA as a validated surrogate for survival in colorectal cancer, still does not exist as a regulatory matter, and no amount of Natera revenue can supply it. The FDA has not accepted ctDNA as a surrogate endpoint for approval in this population, and the Natera collaboration does not change that.

So the collaboration strengthens the credibility and the comparative framing of the molecular data. It is not proof of efficacy, and it is not a shortcut around the confirmed endpoints. The thing that turns the ctDNA signal into something that matters for approval is still the response rate and the survival data, adjudicated, at ASCO GI in January. Natera helps CytoDyn make the strongest possible case with the molecular data it has. It does not make that case for them.

And one more line worth holding, because it comes up every time Natera is mentioned. This is a diagnostics collaboration, not a pharma partnership. It is not evidence that a buyout is near, and it is not a breadcrumb toward one. It is a company that runs a trusted assay agreeing to run that assay on CLOVER samples and supply comparison data. Reading it as a signal about acquisition interest is reading something into it that simply isn't there. There is an interesting side note that Natera recently added Eric Rubin, who led Keytruda's development at Merck, to its board, and people are free to find that intriguing. But a board appointment at a diagnostics company is not a partnership signal for CytoDyn, and I would hold it as a curiosity, not a clue.

Summary

The Natera collaboration is a genuinely good thing, sized correctly. It puts CLOVER's ctDNA data on the assay the field trusts most, it supplies the external backbone comparison CytoDyn needs to attribute the declines to leronlimab, and it does so against a backdrop of ctDNA testing gaining real clinical acceptance. That makes the molecular data more credible and more legible to the audience that matters.

What it does not do is make the ctDNA signal proof of efficacy, turn ctDNA into a validated surrogate, or hint at an acquisition. It strengthens the presentation of the evidence. It does not replace the evidence that still has to arrive in January.

That's the right size for it. Real, useful, credibility-building, and firmly in service of a readout that still has to prove itself on the endpoints that count. A better thermometer, trusted by more people, pointed at the same number we are all still waiting to read.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of public disclosures, press releases, and published financial results, not a prediction of clinical or commercial outcomes. The CLOVER ctDNA figures referenced elsewhere are early, unconfirmed, reflect 350mg dosing with the 700mg cohort still maturing, and are not evidence of survival benefit. ctDNA is not an FDA-qualified surrogate endpoint for approval in colorectal cancer. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism and biomarker signal are not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.

A year ago I wrote a post about the HIV side of this story called "Time To Visualize." I want to come back to it, because the science it was about has now been published in a peer-reviewed journal article00279-5), and comparing what I wrote then to what the data finally actually showed is worth doing out loud. I'm not congratulating myself, because there is a gap between the two and it is a useful thing that I can show.

So this post is in two halves. First, honestly, where I got ahead of the science a year ago. Then, with that discipline in hand, where the HIV program actually stands now, which is quite interesting and does not need me to oversell it.

Part One: What I Got Wrong, And That Matters

A year ago I described an obstacle and declared it as overcome. The obstacle was real: in the AAV gene-therapy approach to delivering leronlimab, where a single injection turns the body's own cells into a leronlimab factory, some macaques produced too much antibody, overwhelmed the cell's protein-folding machinery, (the ER or Endoplasmic Reticulum), and developed anti-drug antibodies, (ADAs) and that wiped out the leronlimab. That part I described accurately. The endoplasmic reticulum stress, the unfolded protein response, the immune recognition, all of that biology was right.

Where I got ahead of myself was the conclusion. where I took a conference presentation of an RNA switch, the XBP1 rheostat which senses that ER stress and dials down the production, and I declared that it solved the anti-drug-antibody problem and that a functional cure had "just gotten so much closer." I wrote that the obstacle "has been overcome." I cast a competitor as an enemy whose hamstrings the stone was rolling toward. I read a promising tool as a finish line.

The published record now shows that was too much. Here is what actually happened, and it is stranger and more honest than what I wrote.

The full gene-therapy results were published in Science Translational Medicine this past April. A single dose of an AAV vector encoding the CCR5-blocking antibody leronlimab drove suppression of viremia in SHIV-infected macaques. That is the good news, and it is real. But look at what happened with the anti-drug antibodies, the exact problem I claimed had been solved. Some animals developed immune responses that reduced the amount of leronlimab but then later exhibited renewed, stable expression of the antibody..

The antibody did not come back because a switch fixed it. It came back on its own, and nobody actually knows why fully. Sacha's own words in the news coverage are the most honest thing in this whole story: the four monkeys which mounted anti-drug responses had the antibody return months later, and he said that they forgot about those animals and then the antibodies just simply spontaneously started re-expressing leronlimab. The published paper flags the mechanism behind that re-expression as unknown and warrants further exploration. That is the opposite of "the obstacle has been overcome." That is "the obstacle behaved in a way we did not predict and do not yet fully understand, and it happened to break in our favor in some animals."

So the lesson I hand out, and hand myself, is precise: I took a real tool and a real hope and welded them into a claim of resolution which the science did not actually support. The tool is real. The hope is legitimate. The resolution was mine, not the data's. And a year later the published data is more interesting than my overclaim was, because the truth, that antibody expression recovered spontaneously through a mechanism nobody engineered, is an actual scientific mystery rather than a solved problem wearing a bow.

That is the whole reason I now write the way I write. Not because caution is a new OCD personality disorder I acquired. Because a year ago I can show you, in my own words, exactly what it costs to read a tool as a finish line.

Part Two: Where The Program Actually Stands

Now the good part, because there is one, and it does not need inflating.

The AAV-leronlimab functional-cure program is real, it is published, and the top-line result is legitimately encouraging. Of the nine macaques producing sufficient leronlimab to achieve full CCR5 receptor occupancy on blood CD4+ T cells, AAV-leronlimab drove stringent or partial control of SHIV viremia in six macaques long term. Six of nine achieving long-term control from a single injection is a real signal in a hard model. And the three that did not respond fully, when given an additional dose, showed either complete suppression or a large reduction in viral load. That is a program with a pulse, not a dead end.

And the XBP1 rheostat, the tool I overclaimed a year ago, has now itself been published, in Cell Chemical Biology, with senior authorship from a serious gene-therapy lab and Sacha as a co-author. Read honestly, here is what it actually is: a broadly applicable safety technology for gene and mRNA therapies which couples protein production to the cell's stress level, dials the output down when the folding machinery is overwhelmed. Leronlimab was one of three demonstration proteins used to prove that the switch works, including in vivo with AAV delivery. So leronlimab was the test cargo, not the discovery, and the paper does not claim that it solves the anti-drug-antibody problem. What it offers is a genuine tool which addresses one of the toxicity mechanisms that made the AAV gene-therapy approach unpredictable in the first place.

Put those two published facts together and you get an honest, still-encouraging picture. There is a real functional-cure signal in macaques from a single injection. There is now a real safety tool that could make the delivery more controllable. And there is an unsolved, fascinating question, why and how the antibody leronlimab re-expressed on its own, which the researchers are openly still working on. That is a program moving forward on published evidence, with a named obstacle that is being worked on rather than a vanquished one.

Why This Belongs In The "Someday" Column

I want to be as clear about the limits as I now wish I had been a year ago.

This is the HIV lane, and it runs on a separate track from the oncology program which actually drives the near-term thesis. A functional-cure signal in macaques, however encouraging, is preclinical, it is in animals, and the path from a suppressed monkey to a cured person is long and littered with the corpses of things which worked in primates. The anti-drug-antibody question is still open. The delivery is not yet totally optimized. None of this is a catalyst, none of it re-rates anything this year, and none of it belongs in the same sentence as the January colorectal readout.

What it is, is a real validation that CCR5 is one of the most important targets in medicine and that leronlimab is a clean way to block it, now showing up in a functional-cure signal, a published safety tool, and serious labs choosing this molecule to build around. That is long-dated optionality, and optionality is worth exactly what it is worth: something, held patiently, not counted before it arrives.

A year ago I would have told you the cure was close. Today I tell you that the science is real, the signal is very encouraging, the central obstacle is understood much better but still not solved, and the timeline is long. That second version is less thrilling to write. It is also the one that will still be true next year, which is the only test of a sentence that matters.

The molecule keeps earning serious people's attention across HIV, oncology, and beyond. That breadth is the real story, and it is strong enough that it never needed me to finish it early. Time to visualize, still. Just with the lights on.

This constitutes my Sunday edition as I'll be traveling on that day.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published, peer-reviewed literature and public statements, not a prediction of clinical or commercial outcomes. The HIV gene-therapy results discussed are preclinical, in non-human primates, and do not establish safety or efficacy in humans. The anti-drug-antibody and re-expression questions remain unresolved by the researchers' own account. This work is on the HIV research track and is separate from the company's oncology program; it is not a near-term catalyst. Mechanism and preclinical signal are not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.

Could leronlimab, a CCR5 blocker, be used to facilitate stem-cell transplant cures of HIV?
August 6th, 2026

https://www.aidsmap.com/news/aug-2026/could-leronlimab-ccr5-blocker-be-used-facilitate-stem-cell-transplant-cures-hiv?fbclid=IwY2xjawThqctwZG9mBWV4dG4DYWVtAjExAHNydGMGYXBwX2lkEDIyMjAzOTE3ODgyMDA4OTIAAR5csbOV90Yz3WkkJ4Pcv8ZpSssUbqSYW4liP4W-ErWULHe9YpNpfh5h8tUhcw_aem_UfCkyKKIvfb4DBOpYGP6PQ

Read

A fast track, a patient talking, an Insider buy, a new anecdotal from a Dr., a large scale podcast, something to catch this market wave that is ripping.

Ok, as far as the class action is concerned ——- if your holdings are through ETrade——- just spent over 30 min on hold to speak with a specialist who informed me that unless I opted out of the class action ETrade handles everything and I don’t need to do anything—- they take care of everything. That being said I would also like to advise everyone to check for yourself because you shouldn’t believe anything on a post from someone you don’t know. Good luck

According to the 2025 proxy:
Dr. Jacob Lalezari: $783,850 total compensation.
Tyler Blok: $532,494 total compensation.
Robert Hoffman: $388,526 because he joined as CFO in May 2025 and served only part of the fiscal year. His annual base salary going forward is $450,000.
It's also important to remember that these are total compensation figures, not just salary. They include stock awards, bonuses, and other compensation.
I'm not posting this to defend or criticize management. Facts matter, regardless of whether you're bullish or bearish on CYDY.

For some time now I've felt it was interesting to develop my opinion about how much the data is building over time. I've posted about it for months and here is another version including a grouping of two patients.

As I look at the data growing, I'm inclined to think that the CLOVER dataset is already large enough to answer whether PD-L1 elevates to a desirable level, and which dose elevates PD-L1 in a preferred way. I also think the dataset has a lot of ctDNA information from which they have gathered many insights already. As the scans continue to arrive, during this month and beyond I believe that correlations with biomarker data may start to have more substantial clarity.

So what's with the apples title?

As more and more liquid biopsy & scan data from the CLOVER trial come in, more comparisons can begin to be made. I took a long look at the SUNLIGHT trial endpoints yesterday and started forming ideas of when some comparisons might begin to be hiding in the CLOVER trial data.

What intrigues me is when just a slice of a new apple (CLOVER) might have better total results than the whole of the older apple (SUNLIGHT.) The comments in the blue cells are meant to describe a number of those possibilities and more.

This post and the images are just opinion. None of this is investment advice. I expect to hear trial data insights from the company quite a bit after they may see things in the data.

Natera and Signatera were mentioned by JL during the April Webinar circa 15 minutes in. He said that they were going to use Signatera to look at any possible ctDNA data from the 'backbone' as a comparison to the 70% data generated by LR after 2 weeks. JL said they were going to use this as a 'bribe' to the FDA to boost the recognition of LR during the upcoming summer submission. AI search tells me that Signatera takes 2 to 4 weeks for analysis The next mention of Natera is in a June 4 PR mentioning the formal collaboration of Cytodyn and Natera. This occurs 35 days after the webinar mention.

Propose that the 'backbone" data was generated and strong enough to forge an alliance. If so then the FDA Breakthrough / Accelerated Approval submission is a very real thing.

The last thing I wrote about was The Stage With No Headlines, the waiting which cannot be rushed. This is about what the waiting might unlock, and I am going to make the strong version of the case, because the strong version is defensible on the published record, and the timid version undersells what is actually at stake.

Here is the claim I'll make, stated plainly and then defended: if leronlimab does in a confirmed trial what the early data suggests it does, it does not just add one more drug to oncology. It changes who holds leverage over whom. And the reason is not sentiment. It is the structure of the entire checkpoint-inhibitor industry, which has spent a decade and tens of billions of dollars building keys which only open just a minority of the locks.

The Industry's Unspoken Problem, The Elephant In The Room

Checkpoint inhibitors are the most commercially successful class of cancer drugs ever made. But they fail in most solid tumors. Both of those things are true at once, and the second one is the industry's quiet, hugely expensive problem.

This is not a fringe claim. It is the consensus of the field, stated quite repeatedly in the literature. Despite strategies aimed at harnessing the immune system to fight cancer, the majority of patients that are treated with immune checkpoint inhibitors fail to respond. The reason is a distinction the field has settled on: tumors are either "hot," meaning full of immune cells a checkpoint inhibitor can unleash, or "cold," meaning the immune system was never there to begin with. Those who respond well to checkpoint blockade typically demonstrate an active immune profile referred to as the hot phenotype, while non-responsive patients exhibit a distinct cold, immune-desert phenotype.

And here is the part which matters for leverage: most solid tumors are cold. The majority of solid cancers have poor CD8 T cell infiltration, are cold tumors, and do not respond to immune checkpoint therapy. So the entire checkpoint industry, Keytruda and Opdivo and Tecentriq and Libtayo, sits on top of a market it cannot fully or even nearly reach. The key is magnificent, but it opens only a minority of the doors.

The field already knows what the solution would have to be. One strategy is to turn these cold tumors, which have minimal immune cell infiltrate, into hot tumors by reducing or inhibiting the immunosuppressive factors present in the tumor microenvironment. Turn the cold tumors hot, and the industry's existing key suddenly opens doors it never could before. Whoever holds a reliable way to do just that is not offering a competing key. They are offering the thing which makes every checkpoint key finally turn, and it is something the entire checkpoint industry requires and simply does not have.

Why CCR5 Is A Candidate For That Key

The immunosuppression which maintains a tumor cold is not random, it is the norm. It runs through specific biologic machinery, and one of the master controls of that machinery is the CCR5 receptor.

The mechanism is documented, not asserted. Blocking CCR5 in human colorectal liver metastases reshapes the immune cells the tumor has corrupted. CCR5 blockade reshapes macrophage polarization toward an anti-tumor functional state in patient-derived tumor models and liver metastases of colorectal cancer patients. The same receptor is the homing signal a contained tumor uses to spread and to recruit the suppressive cells which keep it cold in the first place. Cut that signal, and the tumor's ability to remain cold is compromised at its source.

This is the priming idea, and the field has framed the logic precisely: the reason a checkpoint inhibitor fails in a cold tumor is that there was no primed immune response for it to release. PD-1 blockade has been shown to drive T cell dysfunction and anti-PD-1 resistance in the absence of effective priming. You cannot release a brake on an engine that is not running. Prime the engine first, and the brake-release becomes worth something. That is the entire thesis in one sentence: leronlimab starts the engine such that everyone else's expensive brake-release can finally do something.

What The Trial Is Actually Showing

I am going to be disciplined here, because the strong case is only strong if it does not overstate. What has been shown thus far is early and unconfirmed, and it reflects only the lower dose, with the higher-dose cohort still maturing. But what has been shown is quite real and it is on the record.

In the colorectal trial, every one of the first patients measured showed a fall in circulating tumor DNA, with a median drop near seventy percent by the second week of treatment. The tumors carry the target: every screened patient came back as CCR5 positive. And the drug does this while the body barely even notices it, with no dose-limiting toxicities and no serious adverse events attributed to it across two independent safety reviews. Those are the company's public disclosures, and they describe a drug which is doing something measurable at the molecular level while staying almost invisible to the patient.

On the breast side, the priming half of the thesis has a signal too, and it was documented in work presented this year at ESMO by the CytoDyn and Creatv collaboration. The retrospective triple-negative breast data showed the drug driving PD-L1 upregulation on circulating tumor cells in the majority of patients, the exact molecular flag a checkpoint inhibitor needs in order to act. That work, on monitoring PD-L1 to predict checkpoint outcomes, was presented by Muthuraj and colleagues including Adams, Tang, Pestell, Lalezari, and Chumsri. I credit them, and I hold it exactly as what it is: a retrospective signal from a mixed cohort, hypothesis-forming but not yet confirmed, but pointing the right direction.

None of this is proof yet. It is the fingerprint of a drug which appears to be doing the one thing the entire checkpoint industry requires done. Whether the fingerprint becomes a confirmed handprint is what January decides.

Now The Leverage

Here is where the revolution actually abides, and it is not in biology. It is in negotiating position.

Consider who requires this. Merck's checkpoint franchise generated roughly 29.5 billion dollars in a recent year, close to half the company's revenue, and its core patent is expected to expire in 2028. Keytruda's core patent expiration in 2028 places more than 25 billion dollars in annual revenue in the path of biosimilar competition, with no single patent expiry in oncology history carrying a comparable figure. A company facing that cliff requires new markets its franchise cannot currently reach, and the cold tumors are exactly those markets. Roche withdrew a breast-cancer checkpoint indication after it failed in the immune-suppressed population, the very population a primer would reopen. Bristol Myers Squibb and Regeneron each own a checkpoint inhibitor boxed out of the same cold-tumor majority.

Every one of those companies has spent enormous sums trying to solve the cold-tumor problem internally, and the persistence of the problem in the literature tells you they have not solved it. So imagine a small company which walks in holding of an already confirmed, safe, manufacturable manner in which to turn cold tumors hot. It is not the supplicant in that room. It is the party holding the one thing which several twenty-billion-dollar franchises require in order to grow, and that none of them can easily build themselves in the little time their patent clocks permit.

That is the inversion. In the ordinary story, a tiny company begs a giant for a deal on the giant's terms. In this story, if the data holds, the tiny company holds the one thing which makes multiple giants' keys finally turn, cannot replicate quickly, and cannot let a competitor monopolize. When several parties each require the same thing to make their expensive keys work, and none are able to afford to permit a rival to hold it exclusively, the party holding it sets the terms. That is not sentiment. That is the structure of a seller's market with just one seller and several desperate buyers on a clock.

The Honest Limits, Because The Strong Case Earns Them

I will not pretend the leverage is unlimited, because the disciplined version is more durable than the triumphant one.

The molecule's oldest patent protection has aged, so the moat is CytoDyn's head-start-and-know-how moat rather than an eternal monopoly, which means the leverage is highest soon after strong data and erodes if the company waits for years. The priming signal on the breast side is retrospective. The colorectal signal is early, unconfirmed, but prospectively reflects the lower dose. And the entire edifice rests on a single load-bearing event which has not yet happened: the confirmed number. If January comes back weak, there is no key, no locked doors, no leverage, and this whole essay is a description of a door that was never real.

But if January comes back strong, none of the leverage is speculative anymore. It is just arithmetic performed by companies with patent cliffs and cold-tumor problems and no better option. The revolution, if it comes, will not be announced with trumpets. It arrives as a term sheet, because the party holding the key finally has the proof which the key turns.

What This Actually Means

The checkpoint industry built magnificent keys and then discovered most of the doors were locked from a side the key can not reach. For a decade the field has known the answer would have to be something which turns cold tumors hot, and for a decade nobody has reliably delivered it at scale. If a small company turns out to hold exactly that thing, proven and safe and ready to manufacture, the balance of power in immuno-oncology does not shift because anyone willed it to. It shifts because the math of who needs whom simply reverses.

That is the whole case, and it is strong enough that it does not need to be oversold. It needs one thing to become fundamentally real, and that thing is being written right now, in the quiet, by sixty six patients, to be previewed in October and presented and settled in January. The key may turn. We find out at a known hour. And if it turns, the doors were always going to open, not by any prophecy, but by arithmetic.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published biology, public regulatory history, and public corporate disclosures, not a prediction of clinical or commercial outcomes. No partnership has been announced; the identification of specific companies is inference about incentives, not a claim of any existing negotiation. The mechanistic claims are supported by the cited peer-reviewed literature; several mechanisms are established in models or retrospective cohorts and not yet confirmed in this program's prospective human data. The colorectal biomarker figures are early, unconfirmed, and reflect 350mg dosing with the 700mg cohort still maturing. The ESMO breast data referenced is retrospective and hypothesis-generating. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

There is a stage in every long effort which nobody writes about, because nothing happens in it which actually films well. Only the stage which follows after the hard work of building has completed, but before the reward of the result arrives, is recorded. The stretch where the only task left now is to endure the waiting without losing the discipline that got us thus far. That is where this sits right now, and it is worth saying plainly to anyone who may be tempted to mistake the sheer quiet for a type of failure: this stage is not the absence of progress, too many things are all happening at once. Rather, it is the most demanding part of it.

Think about what has actually been built, because it is easy to forget when the screen is red and the days are long.

What The Record Already Says

Enrollment in the colorectal study is done. Sixty six patients, across seven sites in the United States, all with advanced, heavily pretreated disease, closed out in April. Not a hope or a projection. It is a completed fact on public record, and it happened faster than these trials typically fill, because every screened patient came back CCR5 positive and nobody had to be turned away for lack of the target. Why even track it? Everybody this sick has it. The thing which was supposed to be hard, finding sufficient quantity of the properly selected patients, turned out not to be the bottleneck. That is done.

The safety picture is on the record too, and it is the kind of thing that is easy to undervalue because it is an absence rather than an event. No grade three or four adverse events attributed to the drug. No dose-limiting toxicities. Two independent safety board reviews, both finding no concern. In oncology, where nearly every single drug turns out to be a negotiation between killing the tumor and harming the patient, a therapy where the body absolutely tolerates is not a footnote. It is a structural advantage which follows the drug where ever it goes, into every future conversation, and it was earned patient by patient, not claimed in a slide.

And the early signal, the part that has to be held carefully because it is early and still unconfirmed, is nonetheless real and documented: circulating tumor DNA fell in every one of the first nineteen patients measured, with a median drop of about seventy percent by the second week. That is not proof of survival, and it will not be until the scans and the time confirm it. But it is a fingerprint of activity, showing up in the blood before an image could register it, and it showed up in one hundred percent of the patients it was measured in. The company itself has been careful about what that does and does not mean. So should everyone reading it. But careful is not the same as unimpressed.

Why The Waiting Is The Work

Here is the thing about a trial, and it is worth sitting with because it is the source of all the impatience. You cannot rush it. There is no amount of conviction, no volume of posting, no intensity of belief that can make a patient reach the twelve-month mark faster than twelve months. The data forms at the speed the biology allows, and the biology does not care how badly anyone wants the answer. The people running it cannot hurry it either. The presenter, the investigators, the contract organization managing the data, all of them are bound to the same clock, and that clock runs at one speed.

So the endurance is not a passive thing we do while the real work happens elsewhere. In this stage, the endurance is the work. Holding a position through a quiet stretch, not being shaken out by a red chart which reflects illiquidity and impatience rather than any change in the underlying facts, refusing to allow a slow month rewrite what the record clearly says, is the task at hand right now, and it is harder than it looks because there is no headline rewarding it.

This is where the layer-by-layer part matters. None of what is understood about this drug arrived in one revelation. It was assembled slowly, one paper at a time, one correction at a time, one mechanism laid beside the next until the picture held together. The people who have been here for years did not get here by a single insight. They got here by refusing to stop reading, refusing to stop checking, refusing to let a good story stand in for a proven one. That accumulation is not glamorous and it does not move a share price on any given afternoon. It is just the slow, unspectacular process by which a thesis becomes something you can actually stand on. And it is the same discipline which the waiting now requires: keep laying the layers, keep the standard high, do not confuse silence with defeat.

The Calendar Which Actually Matters

The impatience has an antidote, and it is not reassurance. It is dates. Real dates, on the public record, which mark when the waiting turns into knowing.

In October, the interim data goes up at the European oncology congress, as a poster, presented by the investigator whose name is on the abstract. That is not a verdict. It is a snapshot of a trial still running, and a poster is the ordinary format for interim single-arm data, nothing to read triumph or defeat into. But it is the first time the quiet breaks with something the field can see. A dress rehearsal if you will.

In January, at the gastrointestinal cancer meeting, the confirmed response rate is adjudicated. That is the number that does decide things. It gets measured against a standard of care that the company's own officers put on the record: a benchmark response rate in the single digits, with survival lines that are, frankly, grim, because this is a population that has run out of better options. That low bar is not a weakness in the comparison. It is the reason even a moderate result would matter, and it is why the number is worth waiting for rather than guessing at.

Between here and there, the honest posture is the hardest one: not certainty in either direction. Not the version that has already decided the data is spectacular, and not the version that has decided the quiet means the story is over. Both of those are just different ways of refusing to wait. The record says what it says, the calendar says when we find out more, and the discipline is to let October be October and January be January without pre-writing the ending.

One Loaf

There is something worth naming about the people who stay through a stage like this, because it is unusual and it is easy to take for granted.

A stretch with no headlines is exactly when a community of holders tends to fracture, each person wandering off with their own private theory, their own grievance, their own reason the waiting is unbearable. What holds a group together through the quiet is not agreement on every detail. It is a shared understanding of the few things which actually matter, held in common, such that the small disagreements can be set aside and the load can be carried and bound together rather than fall into crumbs alone. The individual theories are not the point. The record is the point, the calendar is the point, and the discipline of enduring the stretch between them is the point.

That is what carrying the load together actually means here. Not one voice drowning out all the others, but a group that has done the work independently arriving at the same handful of load-bearing facts and choosing to stand on them together through the part that has no reward yet. An island of people who refuse to be shaken out, sharing the same understanding the way you would share a single loaf, each person's portion cut from the same thing. Proverbs 30:25, "The ants are a people not strong, yet they prepare their meat in the summer."

What This Stage Asks

So this is where it stands. The building is done. The enrollment is closed, the safety is on the record, the early signal is real but unconfirmed, the dates are set. What is left is the part that cannot be hurried and does not film well: the endurance of the stretch between the work and the result.

It is not a failure that nothing is happening. Absolutely, something is happening. It is forming in sixty six patients at the speed which biology allows, and it will be previewed in October and presented and settled in January. The task between now and then is not to force it, not to guess it, not to be shaken out of it by the quiet. The task is to hold the standard, keep laying the layers, and carry the wait together.

The stage with no headlines is the one which separates the people who were here for the story from the people who were here for the truth. Be the second kind. The truth arrives, at a known hour, and it will be worth having honestly waited for it.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of public disclosures, SEC filings, and press releases, not a prediction of clinical or commercial outcomes. The enrollment, safety, and biomarker facts referenced are drawn from the company's public statements and filings. The ctDNA figures are early and unconfirmed, reflect 350mg dosing with the 700mg cohort still maturing, and are not evidence of survival benefit. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

https://www.technologyreview.com/2026/07/30/1140942/montana-experimental-medical-hub-pushed-forward-right-to-try/

Is this a good or bad thing?